Ticagrelol Versus Aspirin in Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 169 participants.

Also called NCT03884530

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 169 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03884530
Other papers using this trial's data
  • A pilot study of the ticagrelor role in ischemic stroke secondary prevention European neurology, 2022 DOI, PubMed 34515113
  • A randomized pilot study of the efficacy and safety of loading ticagrelor in acute ischemic stroke Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023-02 DOI, PubMed 36446950, PMC9842543 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03884530. Randomized; no masking; primary purpose treatment. Start 2019-05-01 (actual); primary completion 2020-09-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ticagrelol Versus Aspirin in Ischemic Stroke
Condition
Acute Stroke
Intervention (Drug)
Ticagrelor (Brilique) 90
Intervention (Drug)
Aspirin 75mg
Lead sponsor
Kafrelsheikh University (class: other)
Collaborator
Ain Shams University (class: other)

Record details

Record id
cardio:ct-nct03884530
Content hash
a97ece40f55d105120f3c977e957ac520eae0931def28a1a838b7156683d47df